The program aims to generate evidence to support HPV vaccine introduction and uptake in Nigeria and facilitate the dissemination, adoption, and implementation of research findings, with a timeline of twenty-one (21) months from February 2023 to November 2024 to promote the equitable access and utilisation of the HPV vaccine in Nigeria. Cervical cancer is a significant public health concern, especially in Nigeria, where it is a leading cause of cancer-related deaths among women while the Human papillomavirus (HPV) is the primary cause of this cancer. Vaccination is a safe and effective strategy for preventing it.

In collaboration with the National Institute for Cancer Research and Treatment (NICRAT) and with support from Cancer Research UK (CRUK), we proudly contribute to the National Primary Health Care Development Agency (NPHCDA)’s efforts in rolling out the HPV Vaccine in Nigeria. Our active engagement involves providing crucial evidence to inform the rollout, ensuring that young girls are protected from the risks of cervical and other cancers in the future.


SCIDaR offers dynamic and rewarding opportunities to individuals who desire to gain experience and develop key professional skills while also working to contribute to SCIDaR’s organizational goals within six (6) months.


Our vision is to become a leading organization working to accelerate social, health, and economic development of under- served populations